AIM ImmunoTech Inc.

AIM

Healthcare|Biotechnology|US

$0.15

+0.00 (+1.91%)

Tangible Book / Share

$0.35

Cash / Share

$0.58

Clinical Trials (17)

Trial	Conditions	Phase	Status	Enrollment	Design	Drug
NCT03899987 Aspirin and Rintatolimod With or Without Interferon-alpha 2b in Treating Patients With Prostate Cancer Before Surgery	Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC v8	P2	Active	12	RCT, Open-label	EC Aspirin, Recombinant Interferon Alfa-2b, Rintatolimod
NCT03734692 Systemic Immune Checkpoint Blockade and Intraperitoneal Chemo-Immunotherapy in Recurrent Ovarian Cancer	Ovarian Cancer Recurrent	P1P2	Active	24	Open-label	Rintatolimod, Pembrolizumab, Cisplatin
NCT05927142 Combining Anti-PD-L1 Immune Checkpoint Inhibitor Durvalumab With TLR-3 Agonist Rintatolimod in Patients With Metastatic Pancreatic Ductal Adenocarcinoma for Therapy Efficacy	Metastatic Pancreatic Cancer	P1P2	Active	43	Open-label	Durvalumab, Rintatolimod
NCT00215800 The Study of the Safety and Efficacy of Ampligen in Chronic Fatigue Syndrome	Chronic Fatigue Syndrome, Myalgic Encephalomyelitis	P3	Completed	234	RCT, Double-blind	Ampligen
NCT02432378 Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines	Cancer of Ovary, Cancer of the Ovary	P1P2	Withdrawn	—	RCT, Open-label	Cisplatin + celecoxib + DC vaccine, Cisplatin + CKM + Celecoxib + DC Vaccine
NCT05494697 Ampligen Combined With SOC Versus SOC Alone Following First-Line Therapy in Subjects With LAPC	Pancreatic Cancer	P2	SUSPENDED	90	RCT, Open-label	Rintatolimod
NCT00035581 Safety and Efficacy of Ampligen in the Treatment of HIV Patients Failing HAART	HIV Seropositivity, HIV Infection	P2	Terminated	16	RCT, Open-label	poly I-poly C12U
NCT01545141 Chemokine-Modulatory Regimen for Recurrent Resectable Colorectal Cancer	Colorectal Cancer, Colorectal Carcinoma	P1P2	Terminated	15	RCT, Open-label	Chemokin Modulatory Regimen (5 MU/m2), Chemokin Modulatory Regimen (10 MU/m2), Chemokin Modulatory Regimen (20 MU/m2)
NCT07634094 Intensive Locoregional Chemoimmunotherapy, Intradermal Autologous Alpha-DC1 Vaccines, and Systemic Pembrolizumab for Advanced-Stage Ovarian Cancer	Ovarian Cancer	P2	Not Yet Recruiting	28	Open-label	Paclitaxel, Cisplatin, Bioferon, Rintatolimod, αDC1 Vaccine, Pembrolizumab, Celecoxib
NCT01591473 Safety Study of FluMist With and Without Ampligen	Influenza, Human	P1P2	Terminated	55	RCT, Double-blind	Poly I:Poly C12U 50 ug, Poly I:Poly C12U 200 ug, Poly I:Poly C12U 500 ug, Poly I:Poly C12U 1250 ug, Placebo, FluMist
NCT00035893 The Role of Ampligen in Strategic Therapeutic Intervention (STI) of HAART	HIV Seropositivity, HIV Infection	P2	Completed	40	RCT, Open-label	poly I-poly C12U
NCT04379518 Rintatolimod and IFN Alpha-2b for the Treatment of COVID-19 in Cancer Patients	Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm	P1P2	Terminated	4	Open-label	Recombinant Interferon Alfa-2b, Rintatolimod
NCT00215826 Study of Alferon® LDO (Low Dose Oral) in Normal Volunteers	Severe Acute Respiratory Syndrome	P2	Completed	10	RCT, Open-label	Alferon LDO
NCT00215852 A Randomized, Dose-ranging Study of Alferon LDO in Asymptomatic HIV+ Subjects	HIV Infections	P2	Terminated	17	RCT, Open-label	Alferon LDO
NCT05592418 Study to Evaluate the Efficacy and Safety of Ampligen in Patients With Post-COVID Conditions	Post COVID-19 Condition, Long COVID	P2	Completed	80	RCT, Double-blind	Rintatolimod
NCT03599453 Chemokine Modulation Therapy and Pembrolizumab in Treating Participants With Metastatic Triple-Negative Breast Cancer	Triple -Negative Breast Cancer, Estrogen Receptor Negative	Early P1	Completed	8	Open-label	Celecoxib, Recombinant Interferon Alfa-2b, Rintatolimod, Pembrolizumab
NCT00215813 Ampligen in Chronic Fatigue Syndrome	Chronic Fatigue Syndrome		TEMPORARILY_NOT_AVAILABLE	—	—	Poly I: Poly C12U (Rintatolimod)